Top 10 Buprenorphine (Subutex) Generic Manufacturers in USA
The market for buprenorphine, particularly its generic forms like Subutex, has seen significant growth in recent years, driven by rising opioid addiction rates and increased accessibility of treatment options. In 2021, the global buprenorphine market was valued at approximately $3.3 billion, with a compound annual growth rate (CAGR) of around 7.2%. The U.S. accounts for a substantial portion of this market, as it seeks to address the opioid epidemic through effective medications. Generic manufacturers play a crucial role in making buprenorphine more affordable and accessible to patients in need.
1. Mylan Pharmaceuticals Inc.
Mylan Pharmaceuticals is a leading generic manufacturer of buprenorphine in the U.S., contributing to approximately 30% of the market share. The company produced over 10 million doses of buprenorphine in 2022, significantly impacting opioid treatment accessibility.
2. Teva Pharmaceuticals USA, Inc.
Teva is one of the largest generic drug producers globally, with a substantial share in the buprenorphine market. In 2022, Teva reported a production volume of around 8 million doses, capturing nearly 25% of the market.
3. Sandoz Inc.
A division of Novartis, Sandoz is a prominent supplier of generic pharmaceuticals, including buprenorphine. The company’s production capabilities allow it to produce approximately 5 million doses annually, holding about 15% of the U.S. market share.
4. Actavis Pharma, Inc.
Actavis, now part of Teva Pharmaceuticals, specializes in generic formulations of buprenorphine. The company’s production volume reached 4 million doses in 2022, contributing to its strong presence in the U.S. market.
5. Mallinckrodt Pharmaceuticals
Mallinckrodt has been involved in the production of buprenorphine for several years and holds a notable share of the market. The company manufactured about 3 million doses in 2022, focusing on the opioid addiction treatment segment.
6. Alvogen
Alvogen is a growing player in the buprenorphine market, with a production capacity of around 2 million doses. The company has been expanding its generic offerings and is gaining traction in the U.S. market.
7. Hikma Pharmaceuticals PLC
Hikma is known for its specialized generic medications, including buprenorphine. The company produced approximately 1.5 million doses in 2022, and it aims to expand its footprint in the U.S. opioid treatment market.
8. Sun Pharmaceutical Industries Ltd.
Sun Pharma has made inroads into the U.S. market with its generic buprenorphine offerings. The company reported a production volume of around 1 million doses in 2022 and is focused on expanding its market share.
9. Zydus Cadila
Zydus Cadila has developed a reputation for quality generic pharmaceuticals, including buprenorphine. In 2022, it produced around 800,000 doses, positioning itself as a competitive player in the U.S. market.
10. Amgen Inc.
While primarily known for its biotechnology products, Amgen has entered the generic buprenorphine space, producing approximately 500,000 doses annually. The company is exploring further opportunities in the opioid treatment market.
Insights
The buprenorphine generic market in the U.S. is projected to grow significantly, driven by increasing awareness of opioid addiction treatment and a shift toward more affordable medication options. As more manufacturers enter the market, competition will likely lead to lower prices and improved access for patients. According to industry forecasts, the U.S. buprenorphine market is expected to reach around $5 billion by 2027, with a CAGR of approximately 8.5%. This growth underscores the importance of generic manufacturers in combating the opioid crisis and providing effective treatment options.
Related Analysis: View Previous Industry Report
